Loading
A chemical switch that turns off a DNA-repair gene. When it is off, temozolomide works much better.
O6-methylguanine-DNA methyltransferase repairs the lesion temozolomide creates; promoter methylation silences it in ~40% of glioblastomas. Methylated: median OS ~23 months with chemoradiation; unmethylated: ~13 months with minimal temozolomide benefit, so unmethylated patients are the priority for novel-agent trials (e.g., CheckMate 498, which failed). Assay (MSP, pyrosequencing, methylation array) and cut-off variability persist.
Showing the molecule this term concerns: Temozolomide.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares MGMT promoter methylation, 1p/19q codeletion, Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares DNA methylation arrays and beta values (450k, EPIC), 1p/19q codeletion, DNA methylation profiling, Glioma & glioblastoma.
Shares National Brain Tumor Society (NBTS), 1p/19q codeletion, Astrocytoma, IDH-mutant (grades 2 to 4), Epigenetic reprogramming.
Shares CheckMate 498, CheckMate 548, The blood-brain barrier & brain metastasis, Astrocytoma, IDH-mutant (grades 2 to 4).
Shares National Brain Tumor Society (NBTS), Epigenetic reprogramming, The brain: barrier and sanctuary, DNA methylation profiling.
Shares CheckMate 498, CheckMate 548, The brain: barrier and sanctuary, Glioma & glioblastoma.
Shares EORTC 26981 / NCIC CE.3 (Stupp trial), DNA methylation profiling, Glioma & glioblastoma.
Shares EORTC 26981 / NCIC CE.3 (Stupp trial), Temozolomide, Glioma & glioblastoma.